Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use

Pediatric Pulmonology

Volumn 39, Issue 1, 2005, Pages 15-20

  Al Aloul, M ^a   Miller, H ^a   Alapati, S ^a   Stockton, P A ^a   Ledson, M J ^a   Walshaw, M J ^a  

^a Cardiothoracic Center   (United Kingdom)

Author keywords

Aminoglycosides; Colomycin; Cystic fibrosis; Renal damage

Indexed keywords

AMINOGLYCOSIDE; COLISTIMETHATE;

ADULT; ARTICLE; CREATININE CLEARANCE; CREATININE URINE LEVEL; CYSTIC FIBROSIS; HUMAN; KIDNEY FUNCTION TEST; KIDNEY INJURY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CREATININE; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 10344219968     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20138     Document Type: Article

References (38)

1. Perez-Brayfield MR, Caplan D, Gatti GM, Smith EA, Kirsch AJ. Metabolic risk factors for stone formation in patients with cystic fibrosis. J Urol 2002;167:480-484.
2. Hope B, Hesse A, Browne S, Rietschel E, Michalk D. Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis? Paediatr Nephrol 1998;12:275-279.
3. Orr A, McVean RJ, Webb AK, Dodd ME. Quetionnaire survey of urinary incontinence in women with cystic fibrosis. Br Med J [Clin Res] 2001;322:1521.
4. Kovesi TA, Swartz R, McDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med 1998;64:65-66.
5. Drew JH, Watson AR, Evans JH, Smyth AR. Antibiotics and acute renal failure in children with cystic fibrosis. Paediatr Perinat Drug Ther 2002;5:65-67.
6. Pitt TL, Sparrow M, Warner M, Stefanidon M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003;58:794-796.
7. Spencker FB, Staber L, Lietz T, Scille R, Rodloff AC. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin Microbiol Infect 2003;9:370-379.
8. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-642.
9. Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, Webb KA. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358:557-558.
10. Scott F, Pitt T. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis centres in Great Britain. Pediatr Pulmonol [Suppl] 2003;25:307.
11. Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003;2:19-24.
12. Bennett WM. Aminoglycoside nephrotoxicity. Nephron 1983;35:73-77.
13. Price DJE, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 1970;4:525-527.
14. Reed MD, Vermeulen MW, Stern RC, Cheng PW, Powell SH, Boat TF. Are measurements of urine enzymes useful during aminoglycoside therapy? Pediatr Res 1981;15:1234-1239.
15. Steinkamp G, Lutge M, Wurster U, Schulz-Baldes JG, Grone HJ, Ehrich JH. Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr 1986;145:526-532.
16. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Thakur V, Reisin E, Solomonow M, Baratta R, Agular E, Best R, D'Ambrosia R, Solanky T. Accuracy of formula-derived creatinine clearance in paraplegic subjects. Clin Nephrol 1997;47:237-242.
18. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Group. Second edition. London: UK CF Trust. 2002.
19. Baker LRI. Renal disease. In: Kumar P, Clarke M, editors. Clinical medicine (fifth Edition) New York: W.B. Saunders; 2002. p 587-666.
20. Godson C, Ryan MP, O'Halloran D, Bourke S, Brady HR, FitzGerald MX. Investigation of aminoglycoside nephrotoxicity in cystic fibrosis patients. Scand J Gastroenterol 1988;143:70-73.
21. Bannister KM, Field MF. Clinical physiology of the kidney. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine (third edition) New York: Oxford University Press; 1996. p 3103-3115.
22. Tan KH, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003;167:819-823.
23. Sampson MJ, Drury PL. Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight and serum creatinine. Diabetes Care 1992;15:609-612.
24. Alcanatra P, Goncalves F, Moreira C, Gonzalez MA. Assessment of glomerular filtration rate in a hospital population. Comparison of two methods. Acta Med Port 1998;11:767-772.
25. Guasch A, Cua M, Mithch WE. Early detection and the course of glomerular injury in patients with sickle cell anaemia. Kidney Int 1996;49:786-791.
26. Mirahmadi MK, Byrne C, Barton C, Penera N, Gordon S, Vaziri ND. Prediction of creatinine clearance from serum creatinine in spinal cord injury patients. Paraplegia 1983;21:23-29.
27. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000;22:479-485.
28. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998;35:313-329.
29. Assael BM, Marra G, Tirelli AS, Cavanna G, Claris Appiani A, Giunta A, Amoretti M, Milani S. Renal function in cystic fibrosis. Int J Pediatr Nephrol 1986;7:213-216.
30. Samaniengo-Picota MD, Whelton A. Aminoglycoside induced nephrotoxicity in cystic fibrosis: a case presentation and review of the literature. Am J Ther 1996;3:248-257.
31. Pederssen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high dose tobramycin therapy in cystic fibrosis. Antimicrob Agents Chemother 1987;31:594-599.
32. Akbar A, Rees JH, Nyamugundura G, English MW, Spencer DA, Weller PH. Aminoglycoside - associated hypomagnesaemia in children with cystic fibrosis. Acta Paediatr 1999;88:783-785.
33. Burkle WS. Is tobramycin less nephrotoxic than gentamicin? Clin Pharm 1986;5:514-516.
34. Smyth A, Tan K, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Knox A. A randomised controlled trial of once versus three times daily tobramycin for pulmonary exacerbations of cystic fibrosis (the TOPIC study). Pediatr Pulmonol [Suppl] 2003;25:292.
35. Coifu O, Giwercman B, Pederssen SS, et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish Cystic Fibrosis Centre. Acta Pathol Microbiol Immunol Scand 1994;102:674-680.
36. Elborn JS, Prescott R, Stack B, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection of the lungs. Thorax 2000;55:355-358.
37. Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis (Cochrane review). In: The Cochrane database of systematic reviews. Issue 4. Art no. CDOO2767. DOI: 10.1002/14651858.CDOO2767.
38. Armstrong DS, Nixon GM, Carzino R, Bigham A, Carlin JB, Robins-Browne RM, Grimwood K. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983-987.